A phase II trial indicated that grade ≥3 hypertension occurred in 35% of patients treated with TACE-L-P, possibly attributable to endothelial dysfunction generated by VEGF suppression, exacerbated by the vascular toxicity of ICIs (62). The gene discussed is VEGFA; the disease is Hypertension.